Trial Profile
A Pivotal Study of Derazantinib in Patients With Inoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Gene Fusions or FGFR2 Gene Mutations or Amplifications
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Derazantinib (Primary)
- Indications Cholangiocarcinoma; Liver cancer
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms FIDES-01
- Sponsors ArQule; Basilea Pharmaceutica
- 22 Nov 2022 Status changed from active, no longer recruiting to completed.
- 22 Nov 2022 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Results assessing Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 fusions, mutations or amplifications presented at the 47th European Society for Medical Oncology Congress